Pharma-Bio Serv Reports Q1 2026 Financial Results with Revenue Decline and Increased Net Income

Pharma-Bio Serv, Inc. reported its financial results for the three months ending January 31, 2026, revealing total revenues of approximately $2.3 million, a decrease of about 7% from $2.5 million in the same period last year. The decline in revenue was attributed to reduced project activity in both the European and U.S. consulting markets, which saw a drop of approximately $0.1 million each. Despite the overall revenue decrease, the company experienced a slight improvement in gross profit margin, which increased to 31.5% from 31.1% year-over-year, reflecting a reduction in the cost of services to $1.6 million from $1.7 million.

The company reported a net income of $32,860 for the quarter, a significant increase from $8,536 in the prior year, driven by other income, which rose to $131,025 from $101,842. This increase was primarily due to gains from foreign exchange settlements and the disposition of a vehicle. Selling, general, and administrative expenses decreased slightly to $816,909 from $860,300, contributing to the improved profitability despite the revenue decline. The basic and diluted earnings per share were reported at $0.001, compared to $0.000 in the previous year.

In terms of operational developments, Pharma-Bio Serv has maintained a focus on its core business of compliance consulting services across Puerto Rico, the United States, and Europe. The company has also transitioned its headquarters to a virtual operational model following the expiration of its office lease, which is expected to enhance service delivery while reducing overhead costs. The company continues to explore opportunities for geographic expansion and strengthening its business development infrastructure.

As of January 31, 2026, Pharma-Bio Serv's total assets stood at $13.5 million, a slight decrease from $13.7 million at the end of the previous fiscal year. The company reported current liabilities of $3.3 million, significantly higher than $1.7 million in the prior period, largely due to the declaration of a cash dividend payable to shareholders. The total stockholders' equity decreased to $10.2 million from $11.9 million, reflecting the impact of the dividend payment and retained earnings reduction.

Looking ahead, Pharma-Bio Serv anticipates that its future performance will be influenced by various factors, including economic conditions, industry trends, and potential regulatory changes. The company is actively assessing the impact of recent tax legislation on its operations and is optimistic about its ability to adapt to market challenges. Management believes that the current level of working capital and cash flows from operations will be sufficient to meet anticipated expenses and contractual commitments in the coming months.